Supplementary Legend from Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types

MLA

Henk M.W. Verheul, et al. Supplementary Legend from Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types. Mar. 2023. EBSCOhost, https://doi.org/10.1158/1078-0432.22481000.

APA

Henk M.W. Verheul, Emile E. Voest, Hans Gelderblom, Paul Hamberg, Ann Hoeben, Derk Jan A. de Groot, Mariette Labots, Debbie G.J. Robbrecht, Niven Mehra, Anne M.L. Jansen, Wendy W.J. de Leng, Erik van Werkhoven, Paul Roepman, Laurien J. Zeverijn, Daphne L. van der Velden, J. Maxime van Berge Henegouwen, Louisa R. Hoes, & Hanneke van der Wijngaart. (2023). Supplementary Legend from Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types. https://doi.org/10.1158/1078-0432.22481000

Chicago

Henk M.W. Verheul, Emile E. Voest, Hans Gelderblom, Paul Hamberg, Ann Hoeben, Derk Jan A. de Groot, Mariette Labots, et al. 2023. “Supplementary Legend from Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types,” March. doi:10.1158/1078-0432.22481000.